FERMENTATIVE PRODUCTION OF D-p-HYDROXYPHENYLGLYCINE AND D-PHENYLGLYCINE

Abstract: A new fermentative process for the preparation of D-<i>p</i>-hydroxyphenylglycine (D-HPG) or D-henylglycine (D-PG) in enantiomerically pure form is disclosed. Precursors for the formation of D-HPG and D-PG are withdrawn form the common aromatic amino acid pathway, converted to <i>p</i>-hydroxyphenylglyoxylate or phenylglyoxylate, and are finally converted to D-HPG or D-PG by the action of a stero-inverting D-aminotransferase.

Description: FERMENTATIVE PRODUCTION OF D-p-HYDROXYPHENYLGLYCINE AND D-PHENYLGLYCINE Field of the invention The invention relates to a biochemical process for the preparation of D-p-hydroxyphenylglycine (D-HPG) and D-phenylglycine (D-PG) in enantiomerically pure form. The invention also relates to recombinant microorganisms for the production of D-HPG and D-PG. Hereinafter the abbreviation (H)PG refers to HPG and/or PG; where required the specific enantiomer of (H)PG is mentioned. This invention was made with German Government support under Grant No.0311644 awarded by the BioRegio program of the Bundesministerium fur Bildung und Forschung (BMBF), and with U.S. Government support under Grant No. RO1 AH 4937 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention. Background of the invention Except for glycine, each of the common, naturally occurring amino acids can exist as one of two possible enantiomers. The two enantiomeric forms of an amino acid can be referred to as the D- and the L-configured enantiomer. The enantiomerical purity of compounds which may exist in two enantiomeric forms is generally expressed in terms of its enantiomeric excess (often abbreviated as "e.e."); e.e. can be defined as the difference in the amounts of the two enantiomers divided by the sum of those amounts, the quotient being multiplied by 100 to get a percentage value. In the context of this application enantiomerically pure will mean an e.e. of at least 90%, preferably more than 95%, or even more than 98%. The distinction between the D- and the L-configured enantiomer is made upon whether the conformation of the α-carbon of the amino acid corresponds to the L- or D-form of glyceraldehyde, an arbitrary standard. Most enzymes which act upon amino acids have L-specific binding domains, thus, most naturally occurring proteins comprise only L-amino acids. There are, however, a few exceptions in which D-amino acids are used by and built into microbial cells. Bacterial cells, for example, produce D-glutamate and D-alanine as a precursor material for murein, a typical cell wall component. D-amino acids are typically not produced directly, but rather by conversion of the L-amino acid to the corresponding D-amino acid by the use of an amino acid specific racemase. Racemases catalyze the conversion of L-amino acids to D-amino acids and vice versa. In equilibrium, one finds a racemic (50 %/50 %) mixture of L- and D-enantiomers, hence, racemases cannot be used as a final reaction step for the production of D-amino acids in enantiomerically pure form. An increasing demand for antibacterial drugs has led to a mass production of semisynthetic antibiotics, many of which have incorporated optically active D-amino acids as building blocks. D-HPG and D-PG, e.g., are incorporated in some β-lactam antibiotics, such as amoxicillin and cephalexin. For cost effective production of these antibiotics, it is required to have available a commercially attractive process for the preparation of D-(H)PG in enantiomerically pure form. However, due to their complex structure and due to the occurrence of a chiral center within the molecules, the production of D-(H)PG with conventional chemical methods generally involves multiple steps for the production of a racemic mixture of D- and L-configured (H)PG and then requires additional optical resolution steps to obtain the products in enantiomerically pure form. The additional process steps add to the process costs and render the overall process commercially less attractive. Fermentative processes for the production of fine chemicals are generally known as being commercially attractive for their ability to convert relatively cheap starting material to the product. The reactions involved in fermentative processes are usually highly regio- and stereoselective. They therefore allow the production of complex and enantiomerically pure products in relatively simple processes. For this reason, numerous attempts have been made in the prior art to produce various fine chemicals by fermentation. Methods for the production of D-phenylalanine in a fermentative process using an E. coli strain containing a Bacillus sphaericus stereo-conserving D-aminotransferase, have been described (EP 0736604A2). "Stereo-conserving D-aminotransferases" shall be understood as D-aminotransferases that exclusively produce D-configured amino acids from D-configured amino donors. ■ ' - ,< "Stereo-inverting D-aminotransferases", on the other hand, shall be defined as aminotransferases which use L-configured amino donors and exclusively produce D-configured amino acids. For instance, L-Glu or L-Asp can be used as amino donor in the production of D-PG or D-HPG. In order to provide the D-configured amino donor for the stereo- conserving D-specific aminotransferase reaction in vivo, genes coding for racemases which catalyze the conversion of L-amino acid to D-amino acid and vice versa, must be present in the cell. Hence, the D-configured amino donor is produced intracellularly from the L-configured enantiomer. The intracellular concentration of the D-configured amino donor will be half or less than half of the total intracellular concentration of said molecule (D- plus L-form). Because decreasing concentrations of the D-configured amino donor (an educt) lead to a shift of the equilibrium of the transamination reaction towards the educt side, a racemic mixture of the amino donor (i.e. the use of racemases in combination with stereo-conserving aminotransferases) is unfavorable for the efficient production of the desired D-amino acid. Additionally, cloning a racemase into the cell is costly in labor and it increases the "metabolic burden" of the cell in that the cell has to synthesize an additional enzyme. The precursor metabolites and the energy consumed for the biosynthesis of the racemase are no longer available for cell growth, product formation, etc. The aim of the current invention is to make available an improved fermentative process for the production of D-HPG and D-PG, which overcomes the above mentioned shortcomings. This aim, surprisingly, is achieved in that in the fermentative process phenylpyruvate (PP) or p-hydroxyphenylpyruvate (HPP) are withdrawn from the aromatic amino acid pathway and converted to mandelic acid (MA) or p-hydroxymandelic acid (HMA), respectively, MA or HMA being converted to phenylglyoxylate (PGL) or p-hydroxyphenylglyoxylate (HPGL), respectively, and finally converted to D-PG or D-HPG, respectively, by the action of a stereo- inverting aminotransferase. The application of a stereo-inverting aminotransferase in a fermentative process provides the clear advantages that no racemase activity is required and that the stereo-inverting aminotransferase uses naturally occurring L-configured amino donors (which are present intracellularly in at least twice the concentration of the respective D-enantiomer, when said D-enantiomer was produced from the L-enantiomer by a racemase). The application of a fermentative process allows the utilization of cheap starting materials such as glucose and other sugars for the production of D-(H)PG. Fermentation (and a fermentative process), within the meaning of the invention, shall be understood as the process of cultivating a microorganism in a suitable medium, converting components of a suitable medium to the product by the catalytic activity of cellular components or by spontaneous chemical reactions, and obtaining the product from the cultivation broth and/or from the biomass itself. A suitable medium, within the meaning of the invention, shall be understood as a mixture of substances on which the microorganism can grow, proliferate, and/or which can be converted to the desired product. In a preferred embodiment of the invention, the microorganism applied in the fermentation is selected from a group of microorganisms which replenish HPP and/or PP (in cases where HPP and/or PP are withdrawn from the respective metabolite pool) more efficiently than typically observed in wild type strains. A microorganism selected from said group of microorganisms shall be referred to as having "improved production capabilities" for HPP and/or PP, and to "provide HPP and/or PP at increased availability". The application of a microorganism that provides HPP and/or PP at increased availability is important for the efficient production of D-HPG or D-PG because in a sequence of reactions not only the slowest reaction of the sequence but every enzymatic reaction controls the production rate to a certain extent. Hence, also the conversion from glucose to HPP and/or PP has an influence on the total production of the final product D-HPG or D-PG. Suitable measures to increase the availability of HPP and PP in said microorganisms comprise the selection of microorganisms showing a beneficial spontaneous mutation, the selection of microorganisms that evolve from classical strain improvement programs involving random mutagenesis, and the selection of microorganisms with improved production capabilities that evolved from application of recombinant DNA technology. Suitable measures to increase the availability of HPP and PP, e.g., can be the introduction of feedback resistant mutants of key enzymes or the overexpression of one or several pathway enzymes as reviewed by Berry (1996, TIBTECH, 14: 250-256). Application of recombinant DNA technology can also be directed towards the introduction of phosphoenolpyruvate-independent sugar uptake systems (WO 98/18936), towards the deletion of the phosphotransferase system (PTS) (Berry, 1996, TIBTECH, 14: 250-256) and/or towards an increased availability of phosphoenolpyruvate by modifications of reactions acting on the intracellular phosphoenolpyruvate concentration (Berry, 1996, TIBTECH, 14: 250-256). Appli- cation of recombinant DNA technology can also be directed towards introducing increased intracellular transketolase and/or transaldolase activity (WO 98/18936). Another suitable measure to provide HPP and PP at increased availability is to supply L-tyrosine, respectively L-phenylalanine, in the fermentation medium. L-Tyrosine is readily converted to HPP, whereas L-phenylalanine is readily converted to PP, by the microorganism in a single aminotransferase reaction step. In a preferred embodiment, microorganisms according to the invention, convert PP to MA and/or convert HPP to HMA in a single-step enzymatic conversion catalyzed by p-hydroxymandelate synthase (p-HmaS). The conversion of HPP to HMA by an enzyme named p-HmaS was described by Choroba et al. (2000, J. Am. Chem. Soc, 122 (22): 5389-90). The advantage of using a single enzyme for the conversion of HPP or PP to HMA or MA is that it is usually easier to clone and establish the in vivo activity of a single enzyme as compared to cloning and establishing the activity of multiple enzymes performing the same overall conversion. Alternatively, a microorganism according to the invention converts PP to MA and/or HPP to HMA in a sequence of reactions comprising the reactions from PP or HPP for instance to phenylacetaldehyde or p-hydroxyphenylacetaldehyde to phenylacetate or p-hydroxyphenylacetate to MA or HMA, respectively. This sequence of reactions is deemed a possible metabolic route as it was observed in the degradation of phenylalanine in a basidiomycete by Krings et al. (1996, Journal of Biotechnology, 51 : 123-129)). Microorganisms according to the invention, irrespective of the way in which they produce HMA or MA, convert MA to PGL and/or HMA to HPGL by the enzymatic activity of a mandelate dehydrogenase and/or a p-hydroxymandelate dehydrogenase, respectively. Alternatively, said microorganisms convert MA to PGL and/or HMA to HPGL by the enzymatic activity of an oxygen dependent mandelate oxidase and/or an oxygen dependent p-hydroxymandelate oxidase, respectively. Microorganisms according to the invention are furthermore capable of converting HPGL, respectively PGL, to D-HPG, respectively to D-PG, by the action of a stereo-inverting aminotransferase. The present invention also relates to the production of D-(H)PG by culturing said recombinant cells in a suitable medium and obtaining the product from the culture broth or from the microorganism itself. The present invention also relates to a recombinant microorganism (i.e. to a recombinant cell) which is capable of secreting detectible amounts of D-HPG and/or D-PG and contains genes, coding for enzymes which catalyze in a single step, and/or by combined and subsequent action, the conversion of HPP to HMA and/or of PP to MA, the conversion of HMA to HPGL and/or of MA to PGL, and the conversion of HPGL to D-HPG and/or of PGL to D-PG, the final step being catalyzed by the action of a stereo-inverting D-aminotransferase. It is to be noticed that the production of D-PG and D-HPG using a stereo-inverting aminotransferase is described by Wiyakrutta and Meevootisom (1997, Journal of Biotechnology, 55: 193-203). However, a whole cell fermentative approach is not considered. Instead, the authors mention reactions with purified enzyme. Furthermore, Taylor et al. (1998, TIBTECH, 16: 412-418) mention that the educts, PGL and HPGL, are very expensive, as compared to the value of the final products, D-PG and D-HPG. Thus, these references do not suggest any feasible application of a stereo-inverting aminotransferase for the production of D-HPG or D-PG. Moreover, combination of a fermentative pathway to HPGL or PGL with the enzymatic activity of a stereo-inverting D-aminotransferase in vivo would have been expected to have limited chances of success because of incompatible pH optima of the respective enzymes. The intracellular pH of E. coli cells is reported to be in the range of pH 7.4 to pH 7.8 (Neidhardt et al., 1996, Escherichia coli and Salmonella typhimurium. Cellular and molecular biology., volume 1 , chapter 96, page 1539, ASM Press, Washington, D.C.). The stereo- inverting aminotransferases, however, as reported by Wiyakrutta and Meevootisom (see above) have pH optima at pH 9 to pH 10 and very little activity at neutral pH. Thus, one would expect that a stereo-inverting aminotransferase does not have sufficient in vivo activity in E. coli cells to produce D-HPG or D-PG effectively. Apart from an incompatibility of pH optima, several other problems can be expected, when enzymes from different organisms are combined to a new metabolic pathway in a host cell. The affinity of newly introduced enzymes might be very different from the intracellular metabolite concentrations. Furthermore, the stability of the heterologous enzyme might be low due to a high susceptibility of heterologous proteins towards intracellular proteases. The intermediates of the newly constructed pathway themselves might be unstable or metabolized by native enzymes of the host cell. Problems in the functional expression of the heterologous enzymes can also arise from inappropriate folding of correctly translated amino acid chains or from a difference in codon usage which might hinder the effective functional expression of the heterologous enzyme. Despite the numerous problems that are expected in the construction of the new metabolic pathway, surprisingly, we found that D-HPG and D-PG were produced by recombinant microorganisms in a process according to the invention. Finally, the invention also relates to recombinant plasmids containing at least one gene having a sequence corresponding with any of [SEQ ID: No.9] and/or [SEQ ID: No.15] and/or [SEQ ID: No.21], as disclosed hereinafter in this application, or homologues of any of these sequences having at least 80%, preferably at least 90%, most preferably at least 95% homology with any of such sequences. Other features of the invention will become apparent in the course of the following descriptions of the examples. General procedures Standard molecular cloning techniques such as plasmid DNA isolation, gel electrophoresis, enzymatic restriction modification of nucleic acids, E. coli transformation etc. were performed as described by Sambrook et al., 1989, "Molecular Cloning: a laboratory manual", Cold spring Harbor Laboratories, Cold Spring Harbor, NY. Synthetic oligodeoxynucleotides were obtained from MWG- Biotech AG (Ebersberg, Germany), Sigma-Genosys (The Woodlands, TX, USA), and LifeTechnologies (Paisley, Scotland, UK). DNA sequence analyses were performed by BaseClear (Leiden, The Netherlands), GATC Biotech AG (Konstanz, Germany), and Johns Hopkins University School of Medicine Biosynthesis and Sequencing Facility (Baltimore, MD, USA) using the chain termination method with dye-labeled dideoxy-terminators. Protein concentrations in crude extracts were determined with Bradford reagent at 595 nm (Roth, Karlsruhe, Germany) according to the instructions of the supplier. Experimental Part 1 (Examples 1-19): Cloning and verification of encoded activity of relevant single genes Example 1 : Construction of plasmids pBAD-Ao-HmaS, pBAD-Ao-HmaO, pBAD- Sc-HmaS, pBAD-Sc-HmaO Amycolatopsis orientalis NRRL 18098 (US patent 5,843,437) was obtained from the ARS (Agricultural Research Service) Patent Culture Collection, Peoria, Illinois, USA. A. orientalis was cultivated in 1 % glucose, 0.5 % yeast extract (Difco, Detroit, Michigan, USA), 2 % starch, 0.1 % casamino acids (Difco), pH 7.5 with NaOH at 28°C. Streptomyces coelicolor A3(2), kindly obtained from Professor M.J. Bibb of John Innes Institute, Norwich (UK), was cultivated in YE-ME medium containing 3 g/l yeast extract (Difco), 5 g/l peptone (Difco), 3 g/l malt extract (Oxoid, Basingstoke, UK), 10 g/l glucose, 340 g/l sucrose at 28°C. 10 g/l glycine and 5 mM MgCI 2 were added after sterilisation. , The genomic DNA from A. orientalis and S. coelicolor was isolated by a salting out procedure (Pospiech and Neumann, 1995. Trends Genet. 11 : 217-218). The HmaS and HmaO genes of S. coelicolor and A. orientalis were cloned in expression vector pBAD/ yc-HisC (Invitrogen, Groningen, The Netherlands). Genes were cloned via a translation-start (ATG) fusion and with their original stop codons. 1.1 Construction of plasmid pBAD-Ao-HmaS A 1131 bp fragment comprising the open reading frame (ORF) for p-hydroxymandelate synthase was amplified by PCR from the chromosomal DNA from Amycolatopsis orientalis NRRL18098 (nucleotides 14957-16030 of accession number AJ223998; amplified region nucleotides 14957-16060) using the following primers: 5' - GTCCACGGTCTCCCATGCAGAATTTCGAGAT - 3' [SEQ I D: No.1 ] (with Bsa I recognition and cleavage site underlined), and 5' - ACATCCCAAGCTTCACGTTCGAGGTC - 3' [SEQ ID: No.2] (with Hind III cleavage site underlined). A list of all oligonucleotide sequences used in the context of the present application is presented in Annexe 4 hereto. Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The fragment was digested with the enzymes Bsa I and Hind III to generate sticky ends. The plasmid pBAD/ yc-HisC was digested with Nco I and Hind III. The two fragments were subsequently ligated and used for the transformation of chemically competent cells of E. coli Top10 (Invitrogen, Groningen, The Netherlands). The transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was given the name pBAD-Ao-HmaS, which has been deposited under the Budapest Treaty at the Deutsche Sammlung fur Mikroorganismen und Zellkulturen, Braunschweig, Germany (DSMZ), on October 23 rd , 2000, under deposit number DSM 13786, and was used for further investigations. 1.2 Construction of plasmid pBAD-Ao-HmaO A 1096 bp fragment comprising the ORF for the p-hydroxymandelate oxidase was amplified by PCR from Amycolatopsis orientalis NRRL18098 chromosomal DNA (nucleotides 16027-17100 of accession number AJ223998; amplified region nucleotides 16027-17101) using the following primers: 5' - CGCTCGGTCATGACGTACGTTTCCCTG - 3' [SEQ ID: No.3] (with SspH I cleavage site underlined), and 5' - ACGAAGAAGCTTATCAAACAACCCCCAG - 3' [SEQ ID: No.4] (with Hind III cleavage site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The fragment was digested with the enzymes SspH I and Hind III and the plasmid pBAD/Myc-HisC was digested with Nco I and Hind III. The two fragments were ligated and introduced into E. coli Top10 cells. The transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was called pBAD-Ao-HmaO which has been deposited under the Budapest Treaty at the DSMZ on October 23 rd , 2000, under deposit number DSM 13791 , and was used for further investigations. 1.3 Construction of plasmid pBAD-Sc-HmaS A 1091 bp fragment comprising the ORF for the p-hydroxymandelate synthase was amplified by PCR from Streptomyces coelicolor A3(2) strain M145 chromosomal DNA (encoded by nucleotides 1418- 2533 of accession AL035640; amplified region nucleotides 1415-2494) using the following primers: 5' - ATGCCGCCCAGTGACATCGCGTACGC - 3' [SEQ ID: No.5] and 5' - CCCTCGGTACCAGGTCATCGGCCGGCCACTTCC - 3' [SEQ ID: No.6] (with Kpn I restriction site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The amplified fragment was cloned into the Nco \/Kpn I site of the vector pBAD/Myc-HisC as described by Dietmaier et al. (1993, Nucleic Acids Res. 21 , 3603-3604). The resulting plasmid was introduced into E. co//Top10 cells by electroporation. The transformants were selected on LB agar plates containing 100 mg/l carbenicillin. All colonies resulting from the transformation were collected and the resulting cell suspension was used for plasmid DNA isolation. The total plasmid DNA was digested with Hind III and separated on an agarose gel. A 5 kb DNA fragment being the target plasmid in linear form was isolated from the gel, re-ligated and introduced into chemically competent £. coli Top10 cells by electroporation. The transformants were selected on LB agar plates containing 100 mg/l carbenicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was given the name pBAD-Sc-HmaS which has been deposited under the Budapest Treaty at the DSMZ on October 23 rd , 2000, under deposit number DSM 13790, and was used for further investigations. 1.4 Construction of plasmid pBAD-Sc-HmaO A 1149 bp fragment comprising the ORF for the p-hydroxymandelate oxidase was amplified by PCR from the Streptomyces coelicolor A3(2) strain M145 chromosomal DNA (nucleotides 135-1268 of accession AL035640; amplified region nucleotides 132-1267) using the following primers: 5' - ATGCGGGAGCCGCTCACGCTCGAC - 3' [SEQ ID: No.7] and 5' - CCAACTGGTACCTGGTCATCCGTGGCTCCTGTCTCG - 3' [SEQ ID: No.8] (with Kpn I restriction site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The amplified fragment was cloned into the Nco \/Kpn I site of vector pBAD/Myc-HisC as described by Dietmaier et al. (1993, Nucleic Acids Res. 21 , 3603-3604) and the resulting plasmid was subsequently introduced into £ coli Top10 cells. Transformants were selected on LB agar plates containing 100 mg/l carbenicillin. Plasmid DNA was isolated from all transformants, digested with Hind III and separated on an agarose gel. A 5.2 kb DNA fragment being the target plasmid in linear form was isolated from the gel, re-ligated and introduced into chemically competent £ coli Top10 cells. The transformants were selected on LB agar plates containing 100 mg/l carbenicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was given the name pBAD-Sc-HmaO, which has been deposited under the Budapest Treaty at the DSMZ on October 23 rd , 2000, under deposit number DSM 13789, and was used for further investigations. Example 2: Expression of p-hvdroxymandelate synthase and p-hydroxymandelate oxidase from A. orientalis and S. coelicolor Single colonies of the £ coli Top10 strains harboring the plasmids pBAD-Ao-HmaS or pBAD-Sc-HmaS (for p-hydroxymandelate synthase) and the plasmids pBAD-Ao-HmaO or pBAD-Sc-HmaO (for p-hydroxymandelate oxidase) were cultivated in 50 ml LB medium containing 100 mg/l carbenicillin at 30°C. At OD 620nm 1 -2, the cells were induced by the addition of 0.002 % (final concentration) arabinose. After 3.5 hours the cells were harvested and washed with 1 mM MgSO 4 at pH 7.4. Aliquots of washed cells were frozen at -20°C for later use. As a control, £. coli Top10 harboring plasmid pBAD/Myc-HisC was treated accordingly. Crude extracts were prepared by sonification in 200 mM potassium phosphate buffer pH 7.5 immediately before use. Example 3: Analysis of p-hydroxymandelate synthase from A. orientalis and S. coelicolor 3.1 Activity towards p-hydroxyphenylpyruvate The assay mixture of 3 ml contained 200 mM potassium phosphate buffer pH 7.5, 5 mM p-hydroxyphenylpyruvate, 10 % ethanol (50 mM p-hydroxyphenylpyruvate stock solution in 96 % ethanol was used), 44 mM ascorbate, 0.3 mM FeSO , and cell free extract leading to a final concentration of 0.6 mg/ml of soluble protein. Boiled extracts were used in control experiments. The assay was started by the addition of HPP and stopped after 1 hour at 28°C by the addition of 0.1 ml 1 N HCI to an aliquot of 0.5 ml of the reaction system. The samples were analyzed by HPLC and detected at 215 nm. A Nucleosil-120-5-C18 column (250x4 mm, Macherey-Nagel, Dϋren, Germany) was used. The column was eluted with eluent A (50 mM H 3 PO 4 ) and eluent B (100 % methanol). Gradient: 0-5 min, 0 % B; 5-37 min, 0 % to 90 % B; 37-42 min, 90 % B; 42-50 min, 90 % to 0 % B; 50-55 min, 0 % B. The flow was 1.0 ml/min, the column temperature was set at 30°C. 65 mg/l p-hydroxymandelate was produced within 1 hour with cell free extracts derived from £ co///pBAD-Ao-HmaS, while 35.6 mg/l p-hydroxymandelate was produced with extracts derived from £ co///pBAD-Sc-HmaS. No p-hydroxymandelate was produced in the control experiments (crude extracts of £ co///pBAD/Myc-HisC and boiled extract). 3.2 Activity towards phenylpyruvate The assay mixture of 3 ml contained 200 mM potassium phosphate buffer pH 7.5, 5 mM phenylpyruvate, 44 mM ascorbate and 0.3 mM FeSO 4 and cell free extract at a final concentration of 0.6 mg/ml of soluble protein. The assay was started at 28°C by the addition of the cell free extract and stopped by the addition of 0.1 ml 1 N HCI to an aliquot of 0.5 ml of the reaction system. Samples were analyzed by HPLC as described above. Both boiled extracts and the crude extract of £ co///pBAD//Wyc-HisC were used in control experiments. 63 mg/l mandelate was produced within 1 hour using cell free extract derived from £ co//7pBAD-Ao-HmaS. Cell free extract derived from E. co///pBAD-Sc-HmaS produced 25 mg/l mandelate within 6 hours. No mandelate was detected in the control experiments. Example 4: Analysis of p-hydroxymandelate oxidase from A. orientalis and S. coelicolor 4.1 Activity towards D,L-p-hydroxymandelate 100 μl of the crude extract containing 0.5 - 0.8 mg protein was incubated with 100 mM potassium phosphate buffer pH 7.5, 2 mM D,L-p-hydroxymandelate, 20 mg/l catalase in a total volume of 1 ml. The oxidation of p-hydroxymandelate was monitored spectrophotometrically at 340 nm. To correct for non-specific oxidation of p-hydroxymandelate, control assays were run using an assay mixture without cell free extract. The specific activity was 30 nmo min "1 *mg "1 total protein for the extracts of £ coli Top10/pBAD-Sc-HmaO and 5 nmo min "1 *mg "1 total protein for £ coli Top10/pBAD-Ao-HmaO. 4.2 Activity towards (S)- or (ffl-mandelate The assay mixture of 3 ml contained 100 mM potassium phosphate buffer pH 7.5, 2 mM (S)- or (R)-mandelate, 20 mg/l catalase and cell free extract at a final concentration of 0.6 mg/ml of soluble protein. The assay was started by addition of the cell free extract and stopped by the addition of 0.1 ml 1 N HCI to an aliquot of 0.5 ml of the reaction system. Samples were analyzed by HPLC by the method of Example 3. Boiled extracts were used in control experiments. No phenylglyoxylate was produced with cell free extracts derived from £. co///pBAD-Ao-HmaO or £ co/Z BAD-Sc-HmaO using (R)-mandelate as a substrate. With (S)-Mandelate as a substrate 9 mg/l phenylglyoxylate were produced within 1 hour using cell free extract from £ co///pBAD-Ao-HmaO, and 27 mg/ml phenylglyoxylate was produced within 1 hour with cell free extract derived from £ co///pBAD-Sc-HmaO. Example 5: Construction of plasmids pMAL-Nu-HmaS and pMAL-Nu-HmaO Nocardia uniformis subsp. tsuyamanensis ATCC 21806 was obtained from the American Type Culture Collection (Manassas, VA, USA). N. uniformis was cultivated and genomic DNA was isolated as described in J. Biol. Chem. 1998, 273, 30695-30703. Genes were cloned into the pMAL-c2 expression vector (New England BioLabs, Beverly, MA, USA) with their original stop codons resulting in a maltose-binding protein fusion protein. HmaS was also cloned into pET-29b (Novagen, Madison, WI, USA) as a C-terminal His-6 tagged fusion. 5.1 Construction of plasmid pMAL-Nu-HmaS A 1052 bp fragment comprising the open reading frame (ORF) for p-hydroxymandelate synthase was amplified by PCR from Nocardia uniformis subsp. tsuyamanensis chromosomal DNA (nucleotides 52-1086 of SEQ. ID: No.9, encoding the protein of SEQ.ID: No.10, given in annexe 1 ; amplified region nucleotides 55-1089) using the following primers: 5' - AGAATTCGCGGCACAGGCAGGCAGCG - 3' [SEQ ID: No.11] (with £coR I cleavage site underlined) and 5' - TTATAAGCTTTCAGCGCTCGGTCCGGTGGC - 3' [SEQ ID: No.12] (with Hind III cleavage site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The fragment was digested with £coR I and Hind III. The plasmid pMAL-c2 was digested with £coR I and Hind III and the two fragments were subsequently ligated and transformed by electroporation into £ coli TB1 cells (New England BioLabs, Beverly, MA, USA). The transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was given the name pMAL-Nu-HmaS, which has been deposited under the Budapest Treaty at the ATCC on October 27 th , 2000, under Patent Deposit Designation PTA-2639, and used for further investigations. 5.2 Construction of plasmid pET-Nu-HmaS A 1051 bp fragment comprising the open reading frame (ORF) for p-hydroxymandelate synthase was amplified by PCR from Nocardia uniformis subsp. tsuyamanensis chromosomal DNA (nucleotides 52-1086 of SEQ. ID: No.9, encoding the protein of SEQ.ID: No.10, given in annexe 1 ; amplified region nucleotides 52-1086) using the following primers: 5' - TATACCATGGCGGCACAGGCAGGC - 3' [SEQ ID: No.13] (with Nco I cleavage site underlined) and 5" - TTATAAGCTTGCGCTCGGTCCGGTGGC - 3' [SEQ ID: No.14] (with Hind III cleavage site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment was purified from the gel. The fragment was digested with Nco I and Hind III. The plasmid pET-29b was digested with Nco I and Hind III and the two fragments were subsequently ligated and transformed by electroporation into £ coli BL21 (DE3) cells (Novagen, Madison, WI, USA). The transformants were selected on LB agar plates containing 50 mg/l kanamycin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was given the name pET-Nu-HmaS, which has been deposited under the Budapest Treaty at the ATCC on October 27 th , 2000, under Patent Deposit Designation PTA-2638, and used for further investigations. 5.3 Construction of plasmid pMAL-Nu-HmaO A 1144 bp fragment comprising the ORF for the p-hydroxymandelate oxidase was amplified by PCR from Nocardia uniformis chromosomal DNA (nucleotides 50-1177 of SEQ. ID: No.15, encoding the protein of SEQ.ID: No.16, given in annexe 2; amplified region nucleotides 53-1180) using the following primers: 5' - AGAATTCGGCGTCCGCAACTCCGCAG - 3' [SEQ ID: No.17] (with £coR I cleavage site underlined) and 5' - AATAAGCTTTCAGGGCGCACCTCGCC - 3' [SEQ ID: No.18] (with Hind III cleavage site underlined). Correct size of the amplified fragment was confirmed by agarose gel electrophoresis and the fragment purified from the gel. The fragment and plasmid pMAL-c2 were digested with £coR I and Hind III. The two fragments were ligated and transformed into £ coli TB1 cells by electroporation. The transformants were selected on LB agar containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was named pMAL-Nu-HmaO, deposited under the Budapest Treaty at the ATCC on October 27 th , 2000, under Patent Deposit Designation PTA-2637, and used for further investigations. Example 6: Preparation of p-hvdroxymandelate synthase and p- hvdroxymandelate oxidase from N. uniformis 6.1 Expression of p-hvdroxymandelate synthase (first method) and of p-hvdroxymandelate oxidase Single colonies of the £ coli TB1 strains harboring the plasmids pMAL-Nu-HmaS or pMAL-Nu-HmaO were cultivated in 100 ml LB medium (+ 0.02% glucose) containing 100 mg/l ampicillin at 37°C. At OD 60 o nm 0.6, the cells were induced by the addition of 0.3 mM (final concentration) isopropylthiogalactoside (IPTG). After 3 hours, the cells were harvested, resuspended in buffer (20 mM Tris-HCI pH 7.4, 200 mM NaCI, 1 mM EDTA for HmaO and 20 mM Tris-HCI pH 7.5, 10 mM EDTA, 1 % Triton X-100 for HmaS) and frozen at -20°C for later use. As a control £ coli TB1 cells containing the plasmid pMAL-c2 were treated identically. 6.2 Purification of p-hydroxymandelate synthase (first method) and of p-hvdroxymandelate oxidase Crude extracts of resuspended pellets were prepared by sonication immediately prior to use. Insoluble cell debris was removed from the extract by centrifugation and the resulting cell free extract applied to an amylose resin column. The desired protein was obtained in > 80% purity by elution with buffer (20 mM Tris-HCI pH 7.4, 200 mM NaCI, 1 mM EDTA) containing 10 mM maltose. The partially purified extract was used in further investigations. 6.3 Expression of p-hvdroxymandelate synthase (second method) Single colonies of the £ coli BL21 (DE3) strains harboring the plasmids pET-Nu-HmaS were cultivated in 100 ml LB medium containing 50 mg/l kanamycin at 37°C. At OD 6 oo nm 0.6, the cells were induced by the addition of 1 mM (final concentration) IPTG. After 4 hours, the cells were harvested, resuspended in buffer (50 mM sodium phosphate pH 8, 300 M NaCI, 10 mM imidazole) and frozen at -20°C for later use. 6.4 Purification of p-hvdroxymandelate synthase (second method) A crude extract was prepared by sonication immediately prior to use. Insoluble cell debris was removed from the extract by centrifugation and the resulting cell free extract was batch incubated with Ni-NTA resin (Qiagen, Valencia, CA, USA) for 1 hour at 200 rpm. The CFE-resin slurry was poured into a column and the desired protein was obtained in > 90% purity by elution with buffer (50 mM sodium phosphate pH 8, 300 mM NaCI) containing increasing concentrations of imidazole. The partially purified extract was used in further investigations. Example 7: Activity of p-hvdroxymandelate synthase from N. uniformis The assay mixture of 0.4 ml contained 50 mM Tris-HCI buffer pH 8.0, 5 mM p-hydroxyphenylpyruvate, 0.7% ethanol (50 mg/ml p-hydroxyphenylpyruvate stock solution was used), 0.5 mM dithiothreitol (DTT), 0.1 mM ascorbate, 0.025 mM FeSO , and partially purified HmaS. The assay was started by addition of HmaS and stopped after 1 hour at 30°C by heat inactivation at 100°C, 5 min. Denatured protein was removed by centrifugation and 0.35 ml of the reaction system used in a coupled assay with HmaO. The assay was started with addition of 0.1 mg/ml HmaO and an increase in absorbance at 332 nm was observed due to the oxidaton of p-hydroxymandelate to HPGL. No HPGL was produced in control experiments. Example 8: Activity of p-hydroxymandelate oxidase from N. uniformis The assay mixture of 0.5 ml contained 50 mM Tris-HCI buffer pH 8 and 2 mM (R,S)-p-hydroxymandelic acid. The assay was initiated with the addition of partially purified HmaO at a final concentration of 0.1 mg/ml. Formation of p-hydroxyphenylglyoxylate (HPGL) was monitored spectrophotometrically at 332 nm. No formation of HPGL was observed in the absence of substrate. The specific activity for HmaO was determined to be 240 μmol*min ~1 *mg "1 . In separate experiments with wild-type enzyme purified from N. uniformis, the oxidase was shown to be flavin-dependent and specific for (S)-mandelic acid. Example 9: Construction of plasmids pGEM-mdlB and pGEM-Bldm Pseudomonas putida ATCC 12633 was obtained from the American Type Culture Collection (Manassas, VA, USA). P. putida was cultivated in LB medium (10 g/l Tryptone Peptone (Difco), 5 g/l yeast extract (Difco), 5 g/l NaCI) at 28°C. The genomic DNA from this P. putida strain was isolated after overnight cultivation using the standard protocol described by Ausubel et al. (1990, Current Protocols in Molecular Biology, chapter 2.4.3, step 1 to 9, Whiley- Interscience, New York). The crude chromosomal DNA was treated with RNAse (20 mg/l), and subsequently with phenol/chloroform/isoamyl alcohol (25:24:1) to remove proteins. A 1409 bp fragment comprising the ORF for the (S)-mandelate dehydrogenase was amplified by PCR from the chromosomal DNA from Pseudomonas putida ATCC 12633 (encoded by nucleotides 2251-3432 of accession J05293; amplified region nucleotides 2110-3518) using Taq DNA- polymerase and the following primers: 5' - ACTCGCCAAGGGCTATGGTGTCC - 3' [SEQ ID: No.19] and 5' - GCCAACAGTTCCAACAGCGGTGTG - 3'. [SEQ ID: No.20] Correct size of the amplified fragment was confirmed by agarose gel electrophoresis. The amplified fragment was cloned in vector pGEM-T (Promega, Madison, Wisconsin, USA) and £ co//XL1-Blue MRF' (Stratagene, La Jolla, CA, USA) was transformed therewith. The transformants were selected on LB agar plates containing 100 mg/l ampicillin. Sequencing of the insert of four different clones revealed that all clones had GC instead of CG at position 2291/2292. One of the clones, without additional mutations, and named pGEM-Bldm, has been deposited under the Budapest Treaty at the DSMZ on October 23 rd , 2000, under deposit number DSM 13787. This original deposit, which, wrongfully, has been made under the name pGEM-mdlB but correctly should have been named pGEM-Bldm, was used in further cloning experiments. Another clone, with an additional silent mutation, named pGEM-mdlB, was used to demonstrate the desired activity. It is noted, that in said latter plasmid the orientation of the mandelate dehydrogenase gene matches the orientation of the vector-borne lac promotor. Example 10: Expression of (SVmandelate dehydrogenase from P. putida E. coli XL1-MRF7pGEM-mdlB was cultured in LB medium containing 100 mg/l carbenicillin and 1 mM IPTG. After 16 hours of cultivation at 37°C, cells were harvested by centrifugation and re-suspended in 50 mM potassium phosphate buffer, pH 6.8. Cells were disintegrated by ultrasonic treatment and non-broken cells and cell fragments were removed by centrifugation (5.000 g, 10 min, 4°C). Finally, membranes were collected by an ultra centrifugation step (1 hour, 200.000 g, at 4°C) and then re-suspended in 4 ml of 50 mM potassium phosphate buffer, pH 6.8 and kept on ice. The protein concentration of the membrane fraction was determined by a modified Lowry protein assay (Sandermann and Strominger, 1972, J. Biol. Chem. 247: 5123-5131), in which 1 % of SDS is added to the Lowry reagent A. The membrane fraction contained about 1 mg/ml protein. Example 11 : Proof of activity of the (SVmandelate dehydrogenase The (S)-mandelate dehydrogenase activity was spectrophotometrically determined using 2,6-dichlorophenol-indophenol as acceptor dye by the method of Hegeman (1966, J. Bacteriol. 91 : 1140-1154). Stereoselectivity of (S)-mandelate dehydrogenase was examined by using (S)- or (R)-mandelate as a substrate. Further it was analyzed, whether the (S)-mandelate dehydrogenase can also take p-hydroxymandelate as a substrate. Membrane fractions of £ coli XL1 MRF7pGEM-mdlB led to a detectible change in absorbance at 600 nm within 5 minutes with (S)-mandelate and with (R,S -p-hydroxymandelate as a substrate. With (R)-mandelate, no changes in absorbance were observed. Example 12: Isolation of the D-p-hydroxyphenylglycine aminotransferase (HpgAT) gene The D-p-hydroxyphenylglycine aminotransferase gene was isolated from Pseudomonas putida NCI MB 12565 (National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland, UK). DNA was extracted from exponentially growing cells (OD 620n m 1.9) using the standard protocol described by Ausubel et al. (1990, Current Protocols in Molecular Biology, chapter 2.4.3, step 1 to 9, Whiley-lnterscience, New York). The crude chromosomal DNA was treated with RNAse (20 mg/l), and subsequently with phenol/chloroform/isoamyl alcohol (25:24:1) to remove proteins.The chromosomal DNA was then partially digested with Sau3A I. The digested DNA was run on a 0.6 % agarose gel and DNA fragments between 4 and 10 kb in size were isolated. Vector DNA was prepared by the digestion of 1 μg of pZErO-2 (Invitrogen, Groningen, The Netherlands) with SamH I according to the protocol of Invitrogen. Vector DNA and P. putida chromosomal DNA fragments were ligated with T4 DNA ligase. The ligation mixture was used to transform chemically competent £ coli Top10 cells. Transformants were plated onto LB medium with 50 mg/l kanamycin. In total 5000 colonies were obtained which formed the primary gene library. All 5000 colonies were pooled in LB medium supplemented with 50 mg/l kanamycin. After addition of glycerol to a final concentration of 15 %, the primary gene bank was stored in aliquots of 1 ml at -80°C. Cultures of 1800 colonies were prepared in 150 μl LB medium supplemented with 50 mg/l kanamycin in microtiter plates. The cultures were cultured overnight at 28°C and harvested by centrifugation in an Eppendorf 5804 R centrifuge (Eppendorf, Hamburg, Germany). The cells were washed with 50 mM KPO 4 buffer, pH 7.0, and re-suspended in 180 μl reaction mix (100 mM potassium phosphate, pH 7.0, 15 mM α-ketoglutarate, 0.1 mM pyridoxal-phosphate and 0.5 %v/v Triton X-100). The reaction was started by adding D-p-hydroxyphenylglycine to a final concentration of 5 mM. The OD 340π m in each well was monitored during 20 minutes using an Optimax microtiter plate reader (Molecular Devices, Sunnyvale, California, USA). A negative control (non transformed £ coli Top10) and a positive control (P. putida NCIMB 12565) were treated accordingly. Of 1800 clones screened, one showed significant increase in the OD 340nm relative to the negative control due to the formation of HPGL. This clone contained the P. putida D-HpgAT gene on a 12 kb plasmid, pZErOTagp. Sequencing of pZErOTagp revealed the complete nucleotide sequence of the D-HpgAT gene. The sequence of this gene is listed as nucleotides 51 to 1376 of [SEQ ID: No.21 , encoding the protein of SEQ.ID: No.22], as shown in annexe 3. Example 13: Construction of plasmid pBAD-HpgAT The P. putida D-p-hydroxyphenylglycine aminotransferase gene was subcloned into pBAD//Wyc-HisC using PCR. The HpgAT ORF was amplified using 5'- GTGCACGGTCTCGCATGTCTATTTATAGCGATTATGAACGTAAAAC - 3' [SEQ ID: No.23] and 5'- GTGCACGGTCTCCTCGAGTTAGCCCAGGAGGTTTTCTTCAGC - 3' [SEQ ID: No.24] as primers (with Bsa I recognition and cleavage site underlined), and chromosomal DNA of Pseudomonas putida NCIMB 12565 as template. Correct size (1361 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment was digested with Bsa I. Vector pBAD//Wyc-HisC was digested with Xho I and Nco I. The purified digested pBAD//Wyc-HisC vector and the digested insert DNA were ligated with T4 DNA ligase. £ coli Top10 cells were transformed by electroporation with the recombinant plasmid and plated on LB medium supplemented with 100 mg/l carbenicillin. Colony-PCR was performed and eight PCR positives as well as £ coli Top10/pBAD/Myc-HisC (as negative control) were cultured in LB medium supplemented with 100 mg/l carbenicillin with and without 0.002 % arabinose as an inducer. The cells were harvested and tested for HpgAT activity as described in Example 12. All 8 colonies showed HpgAT activity with arabinose as inducer. One of these colonies, carrying a plasmid showing the correct insert sequence (as confirmed by sequencing), and named £ coli pBAD-HpgAT, was deposited under the Budapest Treaty at the Deutsche Sammlung fur Mikroorganismen und Zellkulturen, Braunschweig, Germany (DSMZ), on October 23 rd , 2000, deposit number DSM 13788^ Example 14: Preparation of cell free extracts £ coli Top10/pBAD-HpgAT was cultured in LB medium supplemented with arabinose (0.002 %) and carbenicillin (100 mg/l) overnight at 28°C. The cells were harvested by centrifugation and cell free extracts were prepared from a suspension (1 g of cells plus 7 ml of 50 mM KPO 4 , pH 7.0) by sonification and subsequent centrifugation. Example 15.a: Activity of the D-HpgAT towards p-hydroxyphenylglyoxylate 3 ml reaction mixture containing 100 mM potassium phosphate buffer pH 7.0, 60 mM L-glutamate, 0.1 mM pyridoxal phosphate and cell free extract (0.27 mg protein, example 14) was incubated in a cuvette at 20°C. This mixture was used as blank in the spectrophotometric activity measurement at 340 nm. The reaction was started by the addition of p-hydroxyphenylglyoxylate (0.67 mM final concentration) into the reaction mixture. The maximum specific activity in this reaction was 110 nmole per minute per mg protein at 20°C. Example 15.b: Activity of the D-HpgAT towards D-PG and D-HPG 4 ml reaction mixture containing 100 mM potassium phosphate buffer pH 8.0, 15 mM α-ketoglutarate, 0.1 mM pyridoxal phosphate, and cell free extract (0.01 mg protein, example 14) was incubated at 30°C. The assay was started by the addition of the substrate D-PG (4 mM). At certain time intervals, aliquots of 1 ml were taken and transferred to 0.4 ml 1 M H 3 PO 4 to stop the reaction. Samples were analyzed by HPLC (Astec Chirobiotic T 250 mm x 4.6 mm 5 μm column, Advanced Separation Technologies, Whippany, NJ, 20 μl injection volume, column temperature 22°C, 1.0 ml/min of 80 % 15 mM ammonium acetate pH 4.1 and 20 % methanol, detection at 215 nm). Within 20 min, 7% of D-PG has been converted to phenylglyoxylate, while in a similar experiment carried out with D-HPG as a substrate, 12% of D-HPG has been converted to p- hydroxyphenylglyoxylate. Example 16: pH optimum of the D-HpgAT pH optimum of the enzyme was determined in 5 ml reaction mixtures containing 100 mM buffer of a certain pH, 6.5 mM p- hydroxyphenylglyoxylate, 0.05 mM pyridoxal phosphate and 100 μl cell free extract (1.35 mg protein, example 14). The reaction was started by adding 300 μmole L-glutamate (at the appropriate pH, 60 mM final concentration). After certain time intervals at 35°C, samples were taken and stopped by the addition of the same volume of 0.2 M H 3 PO 4 . The samples were analyzed by HPLC (Biorad HPX-87C 300 mm x 7.8 mm, 20 μl injection volume, column temperature 80°C, 1 ml/min 5 mM calcium phosphate) and detected at 210 nm. The enzymatic activity was tested in the pH range 5 to 11. KH 2 PO 4 / Na 2 HPO 4 buffer (pH 5 to 8), TRIS-HCI buffer (pH 8 to 9), CHES-NaOH buffer (pH 9 to 10) and CAPS-NaOH buffer (pH 10 to 11) were applied, respectively. The pH optimum of the enzyme was found to be between pH 8.5 and 9. Significant activity was found between pH 6 and pH 7.5. This is in contrast to Wiyakrutta and Meevootisom (1997, J. Biotechnol., 55: 193-203), who could not observe any activity below pH 7.5 of a D-HpgAT from Pseudomonas stutzeri. Example 17: Pyruvate as an amino acceptor for the D-HpgAT The spectrophotometric assay of Example 12 (however, without Triton in the assay mixture) was applied with pyruvate instead of α-ketoglutarate as the amino acceptor. An increase in absorbance could be observed due to the formation of HPGL. Hence, P. putida D-HpgAT is able to use pyruvate as amino acceptor. The aminotransferase of P. stutzeri, described by Wiyakrutta and Meevootisom (1997, J. Biotechnol., 55: 193-203), used α-ketoglutarate as the sole amino acceptor. Example 18: Enantioselectivity of the D-HpgAT (I) The spectrophotometric assay of Example 12 was used to test the activity of D-HpgAT towards L-HPG. No increase in absorption was observed when L-HPG was used as substrate. After adding D-HPG, the absorption started to increase. Hence, the present D-HpgAT is selective for D-p-hydroxyphenylglycine. To test the enantioselectivity for L-glutamate, a 3 ml reaction mixture containing 100 mM potassium phosphate buffer pH 7.0, 60 mM D-glutamate and 0.1 mM pyridoxal phosphate was incubated at 20°C. This mixture was used as blank in the spectrophotometric activity measurement at 340 nm. p-Hydroxyphenylglyoxylate (0.5 mM final concentration) was added to the reaction mixture. After 2 minutes of incubation, the reaction was started by the addition of 20 μl cell free extract (0.27 mg protein, example 14) to the reaction mixture. No decrease in absorption could be identified when D-glutamate was used as substrate. After adding L-glutamate, the absorption started to decrease. Thus, the current D-HpgAT is selective for L-glutamate. Example 19: Enantioselectivity of the D-HpgAT (II) For further proof of the strict enantioselectivity, 2 reaction mixtures (50 ml final volume) containing 100 mM potassium phosphate buffer pH 8.0, 13 mM p-hydroxyphenylglyoxylate, 0.05 mM pyridoxal phosphate and cell free extract (13.5 or 1.35 mg protein, example 14), were pre-incubated at 35°C for 10 minutes. The reaction was started by adding 34.8 mmole L-glutamate, pH 8.0 (final concentration 0J M). Samples (1 ml) were taken after regular intervals, stopped by the addition of 2 ml of 0.2 M H 3 PO and analyzed by HPLC by the method of example 15. Only D-HPG (not L-HPG) was produced in the reaction. Experimental Part II (Examples 20-35): Construction and testing of artificial D-(H)PG biosynthesis operons General considerations for Examples 20-35 As expression vector for the artificial D-(H)PG biosynthesis operon, plasmid pJF119EH was chosen. This broad host range vector, constructed by Fϋrste, et al. (1986, Gene, 48:119-131), is suitable for protein expression in a variety of gram negative bacteria. The pJF119EH expression system uses the IPTG inducible tac promoter and carries the lac repressor (lac l q gene), which keeps the expression of the cloned foreign gene in the absence of the inducer extremely low. In all cases the different genes belonging to the D-(H)PG operon were amplified by PCR from the appropriate plasmids described in example 1 , example 9, and example 13. To ensure the presence of an optimal ribosomal binding site (RBS) in front of those genes, the RBS as it is present in pBAD/Myc-HisC was included. Example 20: Construction of plasmid pJF-Sc-HmaS The S. coelicolor p-hydroxymandelate synthase gene was subcloned in pJF119EH using PCR. The HmaS ORF including RBS was amplified using 5' - GGGAATTCAGGAGGAATTAACCATGCCGCCgAGcGAC - 3' [SEQ ID: No.25] (with £coRI restriction site underlined, start codon double underlined, and change of codon 3 and 4, indicated by non capital letters, to more frequently used ones in £ coli), and 5' - GAATTCCCATATTCTAGAAGGTCATCGGCCGGCCACT - 3' [SEQ ID: No.26] (with Xba I restriction site underlined, and stop codon double underlined) as primers, and pBAD-Sc-HmaS (see example 1.3) plasmid DNA as template. Correct size (1120 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment and the plasmid pJF119EH were digested with £coRI and Xba I. The two fragments were ligated and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was called pJF-Sc-HmaS. Example 21 : Construction of plasmid pJF-Ao-HmaS The A. orientalis p-hydroxymandelate synthase gene was subcloned in pJF119EH using PCR. The HmaS ORF including RBS was amplified using 5' - TGGGAATTCAGGAGGAATTAACCATGCAG - 3' [SEQ ID: No.27] (with £coRI restriction site underlined, and start codon double underlined), and 5' - CGGCCAGGTCTAGATACGTCATCGCCG - 3' [SEQ ID: No.28] (with Xba I restriction site underlined, and stop codon double underlined) as primers, and pBAD-Ao-HmaS (see example 1.1) plasmid DNA as template. Correct size (1115 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment and the plasmid pJF119EH were digested with £coPI and Xba I. The two fragments were ligated and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was called pJF-Ao-HmaS. Example 22: Construction of plasmid pJF-Sc-HmaO The S. coelicolor p-hydroxymandelate oxidase gene was subcloned in pJF119EH using PCR. The HmaO ORF including RBS was amplified using 5' - TGGGTCTAGAGGAGGAATTAACCAISCGcGAGCCG - 3' [SEQ ID: No.29] (with Xbal restriction site underlined, start codon double underlined and change of codon 2, indicated by non capital letters, to a more frequently used one in £ coli) and 5' - GAATTCCCATAGCATGCCTGGTCATCCGTGGCTCC - 3' [SEQ ID: No.30] (with Sph I restriction site underlined, and stop codon double underlined) as primers and pBAD-Sc-HmaO (see example 1.4) plasmid DNA as template. Correct size (1178 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment and the plasmid pJF119EH were digested with Xba I and Sph I. The two fragments were ligated and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was called pJF-Sc-HmaO and used for further investigation. Example 23: Construction of plasmid pJF-Sc-HmaS - Sc-HmaO In this example, the cloned Sc-HmaS and Sc-HmaO from examples 20 and 22 were combined in the expression vector pJF119EH. The Sc- HmaO gene in pJF-Sc-HmaO was excised from the expression vector by digestion with Xba I and Sph I, and this DNA fragment containing the Sc-HmaO gene was purified by gel electrophoresis. Plasmid pJF-Sc-HmaS was digested with Xba I and Sph I, ligated together with the Sc-HmaO Xba I / Sph I fragment and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. Different transformants were selected, plasmid minipreps prepared, and the plasmid DNA analyzed by restriction mapping. A plasmid comprising the two genes in the correct order in pJF119EH was designated pJF-Sc-HmaS - Sc-HmaO and used for further investigation. Example 24: Construction of plasmid pJF-Ao-HmaS - Sc-HmaO In this example, the cloned Ao-HmaS and Sc-HmaO from examples 21 and 22 were combined in the expression vector pJF119EH, in the same way as it has been described for the construction of pJF-Sc-HmaS - Sc- HmaO in example 23. A plasmid comprising the two genes in the correct order in pJF119EH was designated pJF-Ao-HmaS - Sc-HmaO and used for further investigation. Example 25: Construction of plasmid pJF-HpgAT The P. putida D-p-hydroxyphenylglycine aminotransferase gene was subcloned in pJF119EH using PCR. The HpgAT ORF including RBS was amplified using 5' - TTTCCCAAGCTTACAGGAGGAATTAACCATG - 3' [SEQ ID: No.31 ] (with Hind III restriction site underlined, start codon double underlined) and 5' - GTACCAGCTGCAAAGCTTGAGTTAGCCCAG - 3' [SEQ ID: No.32] (with Hind III restriction site underlined, and stop codon double underlined) as primers and pBAD-HpgAT (see example 13) plasmid DNA as template. Correct size (1378 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment and the plasmid pJF119EH were digested with Hind III. The two fragments were ligated and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. Insertion of the desired fragment in same direction as the tac promoter was confirmed using restriction analysis. A plasmid showing the correct insert sequence with the exception of one silent mutation (change of codon 46 from GCG to GCA) was called pJF-HpgAT and used for further investigations. Example 26: Construction of plasmid pJF-Sc-HmaS - Sc-HmaO - HpgAT In this example, the cloned HpgAT of example 25 was subcloned in plasmid pJF-Sc-HmaS - Sc-HmaO of example 23. The HpgAT gene in pJF-HpgAT was excised from the expression vector by digestion with H/t7d III, and the DNA fragment containing the HpgAT gene was purified by gel electrophoresis. Plasmid pJF-Sc-HmaS - Sc-HmaO was digested with Hind III. After dephosphorylation, this fragment was ligated together with the HpgAT Hind III fragment and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. Different transformants were selected, plasmid minipreps prepared, and the plasmid DNA analyzed by restriction mapping. A plasmid comprising the three genes in the correct order and direction in pJF119EH was designated pJF-Sc-HmaS - Sc HmaO - HpgAT and used for further investigation. Example 27: Construction of plasmid pJF-Ao-HmaS - Sc-HmaO - HpgAT In this example, the cloned HpgAT of example 25 was subcloned in plasmid pJF-Ao-HmaS - Sc-HmaO of example 24 in the same way as described for the construction of pJF-Sc-HmaS - Sc-HmaO - HpgAT in example 26. A plasmid comprising the three genes in the correct order in pJF119EH was designated pJF-Ao-HmaS - Sc-HmaO - HpgAT and used for further investigation. Example 28: Construction of plasmid pJF-Sc-HmaS - mdlB - HpgAT In this example, the cloned Sc-HmaO present in pJF-Sc-HmaS - Sc-HmaO - HpgAT (example 26) was exchanged against the mdlB gene of P. putida resulting in plasmid pJF-Sc-HmaS - mdlB - HpgAT. The P. putida mandelate dehydrogenase gene was amplified by PCR including the RBS sequence as it is present in plasmid pBAD/Myc-HisC using 5' - GGGTCTAGAGGAGGAATTAACCATGAGCCAGAATCTCTTT - 3' [SEQ ID: No.33] (with Xba I restriction site underlined, and start codon double underlined) and 5' - CTGCAGAACCAGCATGGTGGTCAGTACTTCACICATGCG - 3' [SEQ ID: No.34] (with Bst XI restriction site underlined, and stop codon double underlined) as primers and pGEM-Bldm (see example 9) plasmid DNA as template. Correct size (1236 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The fragment was digested with Xba I and BstX I. Plasmid pJF- Sc-HmaS - Sc-HmaO - HpgAT was digested with Xba I and Sph I leading to a 7692 bp fragment of the plasmid without HmaO gene. The purified 7692 bp Xba I / Sph I fragment was ligated with the mdlB ORF containing Xba I / BstX I fragment and transformed in £ coli DH5α. Transformants were selected on LB agar plates containing 100 mg/l ampicillin. Different transformants were selected, plasmid minipreps prepared, and the plasmid DNA analyzed by restriction mapping. A plasmid comprising the three genes in the correct order in pJF119EH was designated pJF-Sc-HmaS - mdlB - HpgAT and used for further investigation. Example 29: Construction of plasmid pJF-Ao-HmaS - mdlB - HpgAT In this example, the cloned Sc-HmaO present in pJF-Ao-HmaS - Sc-HmaO - HpgAT (example 27) was exchanged against the mdlB gene of P. putida resulting in plasmid pJF-Ao-HmaS - mdlB - HpgAT, in the same way as described for the construction of pJF-Sc-HmaS - mdlB - HpgAT in example 28. A plasmid comprising the three genes in the correct order in PJF119EH was designated pJF-Ao-HmaS - mdlB - HpgAT and used for further investigation. Example 30: Expression of artificial D-(H)PG cluster on plasmids pJF-Sc-HmaS- Sc-HmaO-HpgAT. pJF-Ao-HmaS-Sc-HmaO-HpgAT. pJF-Sc-HmaS-mdlB- HPQAT. and pJF-Ao-HmaS-mdlB-HpgAT Single colonies of the £ coli DH5α strains harboring the plasmids pJF-Sc-HmaS-Sc-HmaO-HpgAT, pJF-Ao-HmaS-Sc-HmaO-HpgAT, pJF-Sc-HmaS-mdlB-HpgAT, or pJF-Ao-HmaS-mdlB-HpgAT were used to inoculate 10 ml of LB medium containing Ampicillin (100 μg/ml) and incubated at 30°C for 16 hours. 1 ml of these cultures were subsequently used to inoculate 50 ml of the same medium. Cells were grown at 30°C with 180 rpm. At OD 62 o n m 0.8, the cells were induced by the addition of 0.1 mM IPTG. After 4 hours, the cells were harvested and washed with 100 mM potassium phosphate buffer, pH 7.5. Aliquots of washed cells were frozen at -20°C for later use. As a control £ coli DH5α harboring plasmid pJF119EH was treated accordingly. Crude extracts were prepared with B-PER™ (in phosphate buffer) (Pierce, Rockford, Illinois, USA) immediately before use. Example 31 : In vitro production of D-HPG from p-hvdroxyphenylpyruvate The assay mixture of 3 ml contained 200 mM potassium phosphate buffer pH 8.0, 5 mM p-hydroxyphenylpyruvate (HPP), 10% ethanol (50 mM p-hydroxyphenylpyruvate stock solution in 96 % ethanol was used), 44 mM ascorbate, 40 mM L-glutamate, 40 mM NAD + , 0.1 mM pyridoxal phosphate, and cell free extract of example 30 leading to a final concentration of 0.6 mg/ml soluble protein. The assay was started by the addition of HPP and stopped after 65 h at 30°C by the addition of 0.1 ml 1 N HCI to an aliquot of 0.5 ml of the reaction system. The samples were analyzed by HPLC as described in example 3. The amounts of p-hydroxymandelate (HMA), p-hydroxyphenylglyoxylate (HPGL), and D-HPG produced in mg/l are summarized in Tablel . Table l: Plasmid HMA HPGL D-HPG pJF-Sc-HmaS - Sc-HmaO - HpgAT 17 67 9 pJF-Ao-HmaS - Sc-HmaO - HpgAT 0 166 11 pJF-Sc-HmaS - mdlB - HpgAT 37 73 24 pJF-Ao-HmaS - mdlB - HpgAT 0 97 26 pJF119EH 0 0 0 As can be seen, none of these compounds (HMA, HPGL and D-HPG) was detected in control experiments with cell free extracts derived from £ coli DH5α/ pJF119EH. Example 32: In vitro production of D-PG from phenylpyruvate The assay mixture of 3 ml contained 200 mM potassium phosphate buffer pH 8.0, 5 mM phenylpyruvate (PP), 44 mM ascorbate, 40 mM L- glutamate, 40 mM NAD + , 0.1 mM pyridoxal phosphate, and cell free extract of example 30 leading to a final concentration of 0.3 mg/ml soluble protein. The assay was started by the addition of PP and stopped after 39 h at 30°C by the addition of 0.1 ml 1 N HCI to an aliquot of 0.5 ml of the reaction system. The samples were analyzed by HPLC as described in example 3. Within 39 h 32 mg/l D-PG were produced with cell free extracts derived from £ coli DH5α/ pJF-Ao-HmaS - Sc-HmaO - HpgAT, while 27 mg/l D- PG were produced with cell free extracts derived from £ coli DH5α/ pJF-Ao- HmaS - mdlB - HpgAT. No D-PG was detected in control experiments with cell free extracts derived from £ coli DH5α/ pJF119EH. Example 33: Construction of plasmid pCR-Bl-tyrA The tyrA ORF encoding the £ coli chorismate mutase - prephenate dehydrogenase including the original RBS of £ coli (nucleotides 4740 - 5877 of accession AE000346) was amplified using 5' - GCGTGGAAGCTTAAGAGGTTTATTATGGTTGCTGAA - 3' [SEQ ID: No.35] (with Hind III restriction site underlined, and start codon double underlined) and 5' - GTGCACGGTCTCGAGCTGAATTCUACTGGCGATTGTCAT - 3' [SEQ ID: No.36] (with Bsa I recognition and cleavage site underlined, and stop codon double underlined) as primers, and chromosomal DNA of the wild type £ coli strain LJ110 (Zeppenfeld et al 2000) as a template. Correct size (1169 bp) of the amplified fragment was confirmed by agarose gel electrophoresis. The amplified fragment was directly inserted, according to the instruction of the supplier, into the vector pCR®-Blunt ll-TOPO® (Invitrogen, Groningen, The Netherlands) and transformed in chemically competent £ coli Top10 (Invitrogen, Groningen, The Netherlands). The transformants were selected on LB agar plates containing 50 mg/l kanamycin. A plasmid showing the correct insert sequence (as confirmed by sequencing) was called pCR-BI-tyrA and used for further investigations. Example 34: Construction of plasmid pJF- Sc-HmaS - mdlB - HpgAT - tyrA As a host strain for D-HPG production £ coli KB532 (Δ(pΛeA- tyrA), ΔfytR, aroF f r , thiA, Λsc/R17, endAI , supE44) was chosen. KB532 is a L-tyrosine and L-phenylalanine auxotrophic strain. It lacks the genes for fyrA (chorismate mutase/prephenate dehydrogenase), pheA (chorismate mutase/ prephenate dehydratase), and for the global regulator tyrR, and carries aroF"* " encoding a feed back (L-tyrosine) resistant DAHP synthase. Overexpressing the tyrA gene in KB532 leads to a tyrosine producing £ coli strain, and therewith also to a strain delivering higher amounts of p-hydroxyphenylpyruvate. To enable the overexpression of fyrA together with the artificial D-(H)PG operon, the cloned fyrA gene of example 33 was subcloned in plasmid pJF-Sc-HmaS - mdlB - HpgAT of example 28. The fyrA gene together with its RBS in pCR-BI-tyrA was excised from the expression vector by digestion with Hind III and Bsa I, and the DNA fragment containing the fyrA ORF was purified by gel electrophoresis. Partial digestion of plasmid pJF- Sc-HmaS - mdlB - HpgAT with H/r?d III was performed to obtain fragments of the linearised plasmid, because pJF- Sc-HmaS - mdlB - HpgAT contains three Hind III sites. Correct size of the restriction fragments was confirmed by agarose gel electrophoresis and the fragments of 8912 bp corresponding with the linearised plasmid were purified from the gel. After treatment with alkaline phosphatase to prevent recircularisation of the plasmid, these 8912 bp fragments were ligated with the tyrA Hind III / Bsa I fragment. Recombinant plasmids were selected by complementation by transformation in the fyrA- deficient £ coli strain, KB532 (see above) and growth on minimal medium supplemented with 50 mg/l L-phenylalanine and 0.01 mM IPTG. Different transformants were selected, plasmid minipreps prepared, and the plasmid DNA analyzed by restriction mapping. A plasmid comprising the four genes in the correct order and direction in pJF119EH was designated pJF-Sc-HmaS - mdlB - HpgAT - tyrA, the appropriate strain was called KB532/pJF-Sc-HmaS - mdlB - HpgAT - tyrA and used for further investigation. Example 35: Fermentative production of D-HPG The D-HPG production of E. coli KB532/pJF- Sc-HmaS - mdlB - HpgAT - tyrA from glucose was investigated in mineral medium. This mineral medium consisted of Na citrate-3H 2 0 (1.0 g-l "1 ), MgSO 4 -7H 2 O (0.3 g-l "1 ), KH 2 PO 4 ( 3.0 g-r 1 ), K 2 HPO 4 (12.0 g-l "1 ), NaCI (0.1 g-l "1 ), (NH 4 ) 2 SO 4 (5.0 g-r 1 ), CaCI 2 -2H 2 O (15.0 mg-! "1 ), FeSO 4 -7H 2 O (75.0 mg-C 1 ), thiamine-HCI (vitamin B1) (5.0 mg-r 1 ), and L-phenylalanine (0.05 g-l "1 ). Additional minerals were added in the form of a trace element solution (1 mlT 1 ), which trace element solution was composed of AI 2 (SO 4 ) 3 -18H 2 O (2.0 g-l '1 ), CoCI 2 -6H 2 O (0.7 g l "1 ), CuSO 4 -5H 2 O (2.5 g-C ), H 3 BO 3 (0.5 g-l "1 ), MnCI 2 -4H 2 O (20.0 g-l "1 ) Na 2 MoO 4 -2H 2 O (3.0 g-P 1 ), NiSO 4 -6H 2 O (2.0 g-l "1 ), ZnSO 4 -7H 2 O (15.0 g-l "1 ). A stock solution of Glucose (30 g-l "1 ) was autoclaved separately and added to the sterilized medium to a final concentration of 4 g-l "1 . A single colony of the £ coli KB532/pJF- Sc-HmaS - mdlB - HpgAT - tyrA was used to inoculate 10 ml of minimal medium containing ampicillin (100 μg/ml) and incubated at 30°C for 16 hours. 4 ml of this culture was subsequently used to inoculate 50 ml of the same medium and incubated at 33°C and 180 rpm for 24 h. After 12 h at an OD 62 on m of ~ 0.6, the cells were induced by adding 0.1 mM IPTG. A sample of the culture supernatant was adjusted to pH 5.8, lyophilized, and redissolved in D 2 O. 600 MHz 1 H-NMR at 323 K showed the expected resonance spectrum and spiking with a small amount of HPG confirmed the presence of HPG. Redundant evidence was obtained from a 2-D COSY experiment. The amount present was determined to be 5 mg/l. (Besides HPG, 80 mg/l of its precursor p-hydroxyphenylglyoxylate was present, but no p- hydroxymandelate.) Annexe 1.1 [ SEQ ID : No . 9] [CDS for p-hydroxymandelate synthase from Nocardia uniformis subsp . tsuyamanensis ATCC 21806] aaaccgtcta taaatgctgc cggagggcga tcccacggct ggaggttcgt g atg gcg 57 Met Ala 1 gca cag gca ggc age gtg ttc gac ggc atg acg etc gac cac ace gtg 105 Ala Gin Ala Gly Ser Val Phe Asp Gly Met Thr Leu Asp His Thr Val 5 10 15 ttc tac gtc ggc gac gcg gac cgc gcg gcg ggc gag etc ace gac aag 153 Phe Tyr Val Gly Asp Ala Asp Arg Ala Ala Gly Glu Leu Thr Asp Lys 20 25 30 tac ggg ctg gtg gtg etc ggc acg tec gag ace teg teg gtg cgc teg 201 Tyr Gly Leu Val Val Leu Gly Thr Ser Glu Thr Ser Ser Val Arg Ser 35 40 45 50 gtc gcg gtg ggc ggc ggc tec ate egg ctg gtg ttc tec cag gee ate 249 Val Ala Val Gly Gly Gly Ser He Arg Leu Val Phe Ser Gin Ala He 55 60 65 gee gac gac ace ccg get gee gcg tac gtg aag gtg cac ggc gac ggc 297 Ala Asp Asp Thr Pro Ala Ala Ala Tyr Val Lys Val His Gly Asp Gly 70 75 80 gtg gee gac etc gcg ctg ggc gtc gcc gac gcc cgc gee gcg ttc gee 345 Val Ala Asp Leu Ala Leu Gly Val Ala Asp Ala Arg Ala Ala Phe Ala 85 90 95 gag gcg gtg egg egg ggc gcg egg ccg gtg gcc gag ccc ace gag gcc 393 Glu Ala Val Arg Arg Gly Ala Arg Pro Val Ala Glu Pro Thr Glu Ala 100 105 110 gac ggc gcg gtg etc gcc acg ate atg ggc ttc ggc gac gtg gtg cac 441 Asp Gly Ala Val Leu Ala Thr He Met Gly Phe Gly Asp Val Val His 115 120 125 130 ace ttc gtc cag cgc ccc ggc ggc gcg ccc ggc gag gac ccg gag age 489 Thr Phe Val Gin Arg Pro Gly Gly Ala Pro Gly Glu Asp Pro Glu Ser 135 140 145 gcg ggc ggc ctg cgc gtg ctg gac cac ttc gcg gtc tgc etc gag gcg 537 Ala Gly Gly Leu Arg Val Leu Asp His Phe Ala Val Cys Leu Glu Ala 150 155 160 ggc ggg ctg gag ccg ace gtg gcg ttc tac cag gag gtg ctg gac ttc 585 Gly Gly Leu Glu Pro Thr Val Ala Phe Tyr Gin Glu Val Leu Asp Phe 165 170 175 egg gtg gtc ttc gag gag aag ate gtc gtc ggg gcg cag gcg atg aac 633 Arg Val Val Phe Glu Glu Lys He Val Val Gly Ala Gin Ala Met Asn 180 185 190 tec aag gtc gtg cag age acg tec ggc gcg gtc acg ctg ace etc ate 681 Ser Lys Val Val Gin Ser Thr Ser Gly Ala Val Thr Leu Thr Leu He 195 200 205 210 gaa ccg gac ace teg cgc aag ccc ggt cag ate gac gac ttc ate aag 729 Glu Pro Asp Thr Ser Arg Lys Pro Gly Gin He Asp Asp Phe He Lys 215 220 225 aac cac ggt ggc gcg ggc gtg cag cac ate gcc ttc gcc ace gac ggc 777 Asn His Gly Gly Ala Gly Val Gin His He Ala Phe Ala Thr Asp Gly 230 235 240 ate gtg gac gcg gtg cgc egg ttg cgc gag egg ggc gtg gag ctg etc 825 He Val Asp Ala Val Arg Arg Leu Arg Glu Arg Gly Val Glu Leu Leu 245 250 255 ace acg ccc gcc gcc tac tac gac ctg ctg gcg gac cgc etc gga ccg 873 Thr Thr Pro Ala Ala Tyr Tyr Asp Leu Leu Ala Asp Arg Leu Gly Pro 260 265 270 ace egg tac tec acg gcc gag ctg gcc gag ctg aac ctg ctg gtc gac 921 Thr Arg Tyr Ser Thr Ala Glu Leu Ala Glu Leu Asn Leu Leu Val Asp 275 280 285 290 gag gac cag gac ggc aag ctg tac cag ate ttc gcc egg tec ace cac 969 Glu Asp Gin Asp Gly Lys Leu Tyr Gin He Phe Ala Arg Ser Thr His 295 300 305 ccc agg ggc acg ttc ttc ttc gag ate ate gag cgc gcg ggc gcg cac 1017 Pro Arg Gly Thr Phe Phe Phe Glu He He Glu Arg Ala Gly Ala His 310 315 320 ace ttc ggc age ggc aac ate aag gcc etc tac gag gcc gtc gag gcc 1065 Thr Phe Gly Ser Gly Asn He Lys Ala Leu Tyr Glu Ala Val Glu Ala 325 330 335 gag cgc cac egg ace gag cgc tgagcgcggg gcacggcgat ggacccgctg 1116 Glu Arg His Arg Thr Glu Arg 340 345 cgcgccggtg acctgcacgg ctcg 1140 Annexe 1.2 [SEQ ID: No.10] [p-hydroxymandelate synthase from Nocardia uniformis subsp. tsuyamanensis ATCC 21806] Met Ala Ala Gin Ala Gly Ser Val Phe Asp Gly Met Thr Leu Asp His 1 5 10 15 Thr Val Phe Tyr Val Gly Asp Ala Asp Arg Ala Ala Gly Glu Leu Thr 20 25 30 Asp Lys Tyr Gly Leu Val Val Leu Gly Thr Ser Glu Thr Ser Ser Val 35 40 45 Arg Ser Val Ala Val Gly Gly Gly Ser He Arg Leu Val Phe Ser Gin 50 55 60 Ala He Ala Asp Asp Thr Pro Ala Ala Ala Tyr Val Lys Val His Gly 65 70 75 80 Asp Gly Val Ala Asp Leu Ala Leu Gly Val Ala Asp Ala Arg Ala Ala 85 90 95 Phe Ala Glu Ala Val Arg Arg Gly Ala Arg Pro Val Ala Glu Pro Thr 100 105 110 Glu Ala Asp Gly Ala Val Leu Ala Thr He Met Gly Phe Gly Asp Val 115 120 125 Val His Thr Phe Val Gin Arg Pro Gly Gly Ala Pro Gly Glu Asp Pro 130 135 140 Glu Ser Ala Gly Gly Leu Arg Val Leu Asp His Phe Ala Val Cys Leu 145 150 155 160 Glu Ala Gly Gly Leu Glu Pro Thr Val Ala Phe Tyr Gin Glu Val Leu 165 170 175 Asp Phe Arg Val Val Phe Glu Glu Lys He Val Val Gly Ala Gin Ala 180 185 190 Met Asn Ser Lys Val Val Gin Ser Thr Ser Gly Ala Val Thr Leu Thr 195 200 205 Leu He Glu Pro Asp Thr Ser Arg Lys Pro Gly Gin He Asp Asp Phe 210 215 220 He Lys Asn His Gly Gly Ala Gly Val Gin His He Ala Phe Ala Thr 225 230 235 240 Asp Gly He Val Asp Ala Val Arg Arg Leu Arg Glu Arg Gly Val Glu 245 250 255 Leu Leu Thr Thr Pro Ala Ala Tyr Tyr Asp Leu Leu Ala Asp Arg Leu 260 265 270 Gly Pro Thr Arg Tyr Ser Thr Ala Glu Leu Ala Glu Leu Asn Leu Leu 275 280 285 Val Asp Glu Asp Gin Asp Gly Lys Leu Tyr Gin He Phe Ala Arg Ser 290 295 300 Thr His Pro Arg Gly Thr Phe Phe Phe Glu He He Glu Arg Ala Gly 305 310 315 320 Ala His Thr Phe Gly Ser Gly Asn He Lys Ala Leu Tyr Glu Ala Val 325 330 335 Glu Ala Glu Arg His Arg Thr Glu Arg 340 345 Annexe 2.1 [SEQ ID: No.15] [CDS for p-hydroxymandelate oxidase from Nocardia uniformis subsp. tsuyamanensis ATCC 21806] ceeegcgegt ggggaggcgg cgtgccegac ggacaggagg eaacgagec atg ggc gtc 58 Met Gly Val 1 cgc aac tec gca ggg ggc ggc gcg gaa gac ccc gag gac ctg get gag 106 Arg Asn Ser Ala Gly Gly Gly Ala Glu Asp Pro Glu Asp Leu Ala Glu 5 10 15 gtg gaa egg gcc gcc gcc gcc egg ctg ccg ggg gac gtg cgc gac ttc 154 Val Glu Arg Ala Ala Ala Ala Arg Leu Pro Gly Asp Val Arg Asp Phe 20 25 30 35 ate gcg ggc ggc age ggc gac gag gtg acg ctg gcc gcc aac cgc gcg 202 He Ala Gly Gly Ser Gly Asp Glu Val Thr Leu Ala Ala Asn Arg Ala 40 45 50 gcg etc gac gac gtg gcc ctg etc ccc agg gtg etc gcg ggt gtc cag 250 Ala Leu Asp Asp Val Ala Leu Leu Pro Arg Val Leu Ala Gly Val Gin 55 60 65 gcg gcc gac acg age ace teg etc gtg ggc acg gcg gcc acg ctg ccc 298 Ala Ala Asp Thr Ser Thr Ser Leu Val Gly Thr Ala Ala Thr Leu Pro 70 75 80 gtc gcc gtg gcg ccg atg ggc tac cag tgc etc gtc cac ccc gac ggc 346 Val Ala Val Ala Pro Met Gly Tyr Gin Cys Leu Val His Pro Asp Gly 85 90 95 gag gtc gcg get gcc gcc gcg gcg ggc gcc gcc ggc gtc ccc ttc ace 394 Glu Val Ala Ala Ala Ala Ala Ala Gly Ala Ala Gly Val Pro Phe Thr 100 105 110 115 gtc ggc acg ctg age age egg teg gtc gag gag ate gcc gag ace ggc 442 Val Gly Thr Leu Ser Ser Arg Ser Val Glu Glu He Ala Glu Thr Gly 120 125 130 gcg teg ctg tgg ttc cag etc tac tgg ctg cgc gat cgc ggc ctg gtc 490 Ala Ser Leu Trp Phe Gin Leu Tyr Trp Leu Arg Asp Arg Gly Leu Val 135 140 145 gcc gaa etc gtg gcg egg gcc gag gcg gcg ggc tgc egg gcg ctg gtg 538 Ala Glu Leu Val Ala Arg Ala Glu Ala Ala Gly Cys Arg Ala Leu Val 150 155 160 ate ace gtg gac gtg ccg gtg atg ggc cgc agg etc egg gac gtg cgc 586 He Thr Val Asp Val Pro Val Met Gly Arg Arg Leu Arg Asp Val Arg 165 170 175 aac ggg ate ace ctg ccc egg ace gtc egg gcc gtc cac etc gcc gac 634 Asn Gly He Thr Leu Pro Arg Thr Val Arg Ala Val His Leu Ala Asp 180 185 190 195 ggc ccg tea tec gcg cac gag ccg cgc cag gtc ggc tec ggc gtc gcc 682 Gly Pro Ser Ser Ala His Glu Pro Arg Gin Val Gly Ser Gly Val Ala 200 205 210 cag cac acg age gcg gtc ttc gac ccc gcg ttc ggg tgg cgc gac ctg 730 Gin His Thr Ser Ala Val Phe Asp Pro Ala Phe Gly Trp Arg Asp Leu 215 220 225 gag tgg ctg egg gcg cgc ace agg etc ccc ctg gtg gtc aag ggc gtg 778 Glu Trp Leu Arg Ala Arg Thr Arg Leu Pro Leu Val Val Lys Gly Val 230 235 240 etc gac ccg cgc gac gcc ace agg tgc gtc gag ctg ggc gcc teg gcg 826 Leu Asp Pro Arg Asp Ala Thr Arg Cys Val Glu Leu Gly Ala Ser Ala 245 250 255 gtg gtg gtg tec aac cac ggc ggg egg cag etc gac ggc gcg gcg ccc 874 Val Val Val Ser Asn His Gly Gly Arg Gin Leu Asp Gly Ala Ala Pro 260 265 270 275 age gcg gtg gcc ctg ccg cgc gtc gtc gac gcg gtg gcg ggc gcg gcc 922 Ser Ala Val Ala Leu Pro Arg Val Val Asp Ala Val Ala Gly Ala Ala 280 285 290 gag gtg ctg ttc gac age ggc gtc cgc ggc ggc gtc gac gtg ctg cgc 970 Glu Val Leu Phe Asp Ser Gly Val Arg Gly Gly Val Asp Val Leu Arg 295 300 305 gcc etc gcg etc ggc gcg ace ggc gtg ctg etc ggc cgc cca ate ctg 1018 Ala Leu Ala Leu Gly Ala Thr Gly Val Leu Leu Gly Arg Pro He Leu 310 315 320 tgg ggg etc gcg gtc ggc ggc gag cgc ggc gcg gcg egg gtg ctg gaa 1066 Trp Gly Leu Ala Val Gly Gly Glu Arg Gly Ala Ala Arg Val Leu Glu 325 330 335 ctg ctg cgc ace gag ttc gcg cag gcc ctg ctg etc gcc ggg tgc gcc 1114 Leu Leu Arg Thr Glu Phe Ala Gin Ala Leu Leu Leu Ala Gly Cys Ala 340 345 350 355 gac gtc gac gcg gcc agg gga etc gcg ace gcg cag gcc gcg ccg ace 1162 Asp Val Asp Ala Ala Arg Gly Leu Ala Thr Ala Gin Ala Ala Pro Thr 360 365 370 egg cga ggt gcg ccc tgaccgcctc ggggaccgcg atcggggccg gggcgcgggg 1217 Arg Arg Gly Ala Pro 375 tcaggggaag 1227 Annexe 2.2 [SEQ ID: No.16] [p-hydroxymandelate oxidase from Nocardia uniformis subsp. tsuyamanensis ATCC 21806] Met Gly Val Arg Asn Ser Ala Gly Gly Gly Ala Glu Asp Pro Glu Asp 1 5 10 15 Leu Ala Glu Val Glu Arg Ala Ala Ala Ala Arg Leu Pro Gly Asp Val 20 25 30 Arg Asp Phe He Ala Gly Gly Ser Gly Asp Glu Val Thr Leu Ala Ala 35 40 45 Asn Arg Ala Ala Leu Asp Asp Val Ala Leu Leu Pro Arg Val Leu Ala 50 55 60 Gly Val Gin Ala Ala Asp Thr Ser Thr Ser Leu Val Gly Thr Ala Ala 65 70 75 80 Thr Leu Pro Val Ala Val Ala Pro Met Gly Tyr Gin Cys Leu Val His 85 90 95 Pro Asp Gly Glu Val Ala Ala Ala Ala Ala Ala Gly Ala Ala Gly Val 100 105 110 Pro Phe Thr Val Gly Thr Leu Ser Ser Arg Ser Val Glu Glu He Ala 115 120 125 Glu Thr Gly Ala Ser Leu Trp Phe Gin Leu Tyr Trp Leu Arg Asp Arg 130 135 140 Gly Leu Val Ala Glu Leu Val Ala Arg Ala Glu Ala Ala Gly Cys Arg 145 150 155 160 Ala Leu Val He Thr Val Asp Val Pro Val Met Gly Arg Arg Leu Arg 165 170 175 Asp Val Arg Asn Gly He Thr Leu Pro Arg Thr Val Arg Ala Val His 180 185 190 Leu Ala Asp Gly Pro Ser Ser Ala His Glu Pro Arg Gin Val Gly Ser 195 200 205 Gly Val Ala Gin His Thr Ser Ala Val Phe Asp Pro Ala Phe Gly Trp 210 215 220 Arg Asp Leu Glu Trp Leu Arg Ala Arg Thr Arg Leu Pro Leu Val Val 225 230 235 240 Lys Gly Val Leu Asp Pro Arg Asp Ala Thr Arg Cys Val Glu Leu Gly 245 250 255 Ala Ser Ala Val Val Val Ser Asn His Gly Gly Arg Gin Leu Asp Gly 260 265 270 Ala Ala Pro Ser Ala Val Ala Leu Pro Arg Val Val Asp Ala Val Ala 275 280 285 Gly Ala Ala Glu Val Leu Phe Asp Ser Gly Val Arg Gly Gly Val Asp 290 295 300 Val Leu Arg Ala Leu Ala Leu Gly Ala Thr Gly Val Leu Leu Gly Arg 305 310 315 320 Pro He Leu Trp Gly Leu Ala Val Gly Gly Glu Arg Gly Ala Ala Arg 325 330 335 Val Leu Glu Leu Leu Arg Thr Glu Phe Ala Gin Ala Leu Leu Leu Ala 340 345 350 Gly Cys Ala Asp Val Asp Ala Ala Arg Gly Leu Ala Thr Ala Gin Ala 355 360 365 Ala Pro Thr Arg Arg Gly Ala Pro 370 375 Annexe 3.1 [SEQ ID: No.21] [CDS for D-p-hydroxyphenylglycine aminotransferase from Pseudomonas putida NCIMB 12565] tcagttaact gccatgtaat ctcaaaaacc agtccaatag aggcatcagc atg tct 56 Met Ser 1 att tat age gat tat gaa cgt aaa acg gtg ggc tec gcg cat tgg gcg 104 He Tyr Ser Asp Tyr Glu Arg Lys Thr Val Gly Ser Ala His Trp Ala 5 10 15 gat egg gca cga get gta atg cca gat ggc gta acg get gat aca cgt 152 Asp Arg Ala Arg Ala Val Met Pro Asp Gly Val Thr Ala Asp Thr Arg 20 25 30 gtt ttt gat ccg cat ggg ctg tac ate tgt gac gcg caa ggt gtt cac 200 Val Phe Asp Pro His Gly Leu Tyr He Cys Asp Ala Gin Gly Val His 35 40 45 50 aag ace gat gtt gat ggc aac gta tac ctg gat ttt ttt ggt ggg cat 248 Lys Thr Asp Val Asp Gly Asn Val Tyr Leu Asp Phe Phe Gly Gly His 55 60 65 ggc get tta gtg ctt ggt cat gga cat cca cgt att aac aag gca ate 296 Gly Ala Leu Val Leu Gly His Gly His Pro Arg He Asn Lys Ala He 70 75 80 tct gca gcg ctg acg cat ggc gtc caa tac ggt gca age cat ccg ctt 344 Ser Ala Ala Leu Thr His Gly Val Gin Tyr Gly Ala Ser His Pro Leu 85 90 95 gaa gtg cga tgg gcc gag cgc ttg gtc aac gcc ttc cct teg atg cat 392 Glu Val Arg Trp Ala Glu Arg Leu Val Asn Ala Phe Pro Ser Met His 100 105 110 aaa gtg cgc ttt gcc ggc age ggc act gag gcg act tta ttg gca ctg 440 Lys Val Arg Phe Ala Gly Ser Gly Thr Glu Ala Thr Leu Leu Ala Leu 115 120 125 130 cga atg gcg egg gcg ttt act ggc agg teg aaa ata eta cgt att gcc 488 Arg Met Ala Arg Ala Phe Thr Gly Arg Ser Lys He Leu Arg He Ala 135 140 145 ace cac tat cat ggc tgg cat gac ttc tec gcc tct ggt tac aac agt 536 Thr His Tyr His Gly Trp His Asp Phe Ser Ala Ser Gly Tyr Asn Ser 150 155 160 cac ttc gac ggc cag cca gca ccg ggc gtc ctt get gaa att gca cag 584 His Phe Asp Gly Gin Pro Ala Pro Gly Val Leu Ala Glu He Ala Gin 165 170 175 age aca eta ctg gtt cgc cca gat gac ttc gaa gga tta cgc gca eta 632 Ser Thr Leu Leu Val Arg Pro Asp Asp Phe Glu Gly Leu Arg Ala Leu 180 185 190 ttc get caa tac ggc ggt gag att gcg ace att att gcg gag cca gtc 680 Phe Ala Gin Tyr Gly Gly Glu He Ala Thr He He Ala Glu Pro Val 195 200 205 210 ggc tct cat ttc ggt ate act ccg gtc age gac gat ttc ttg eta gaa 728 Gly Ser His Phe Gly He Thr Pro Val Ser Asp Asp Phe Leu Leu Glu 215 220 225 ggc gcc gcg ctg get cga aag cac ggt gca ata ttc att ctt gac gaa 776 Gly Ala Ala Leu Ala Arg Lys His Gly Ala He Phe He Leu Asp Glu 230 235 240 gtg ata ace ggt ttt cgc gtg ggt aac cac ggt atg cag ggg ctt etc 824 Val He Thr Gly Phe Arg Val Gly Asn His Gly Met Gin Gly Leu Leu 245 250 255 gac att gca ccg gat ctt acg tgc ttg gcc aag gcc agt get gga ggt 872 Asp He Ala Pro Asp Leu Thr Cys Leu Ala Lys Ala Ser Ala Gly Gly 260 265 270 ctt cct gga ggc gta gtc gga gga agg gcg gat gtc atg gcg gta ctg 920 Leu Pro Gly Gly Val Val Gly Gly Arg Ala Asp Val Met Ala Val Leu 275 280 285 290 gat cgc ggt tea gac cgt aag gtt ctg cat caa ggc ace ttc ace gga 968 Asp Arg Gly Ser Asp Arg Lys Val Leu His Gin Gly Thr Phe Thr Gly 295 300 305 aac cca att acg gcg gcg gca gca ate gcg gcg ate gat ace att ate 1016 Asn Pro He Thr Ala Ala Ala Ala He Ala Ala He Asp Thr He He 310 315 320 gaa gat gac gtg tgc aca cac ate aat gcc etc ggt caa tac gcc egg 1064 Glu Asp Asp Val Cys Thr His He Asn Ala Leu Gly Gin Tyr Ala Arg 325 330 335 gac teg atg aac gaa etc ttc get cgt aag cat ttg gac tgg ttg get 1112 Asp Ser Met Asn Glu Leu Phe Ala Arg Lys His Leu Asp Trp Leu Ala 340 345 350 tat ggc cgc ttt tec ggc ttc cac ctg atg ccg gga tta tct ccg ctg 1160 Tyr Gly Arg Phe Ser Gly Phe His Leu Met Pro Gly Leu Ser Pro Leu 355 360 365 370 ace act gac acg ggt gtg ate act cgc gga gaa gtt gca egg ccc gca 1208 Thr Thr Asp Thr Gly Val He Thr Arg Gly Glu Val Ala Arg Pro Ala 375 380 385 gta aaa atg att gcc get atg cgc atg gca tta ate ctt gag ggc ate 1256 Val Lys Met He Ala Ala Met Arg Met Ala Leu He Leu Glu Gly He 390 395 400 gat att ggt ggc cgt gga tct gtg ttt etc tct gcg cag cat gat cgc 1304 Asp He Gly Gly Arg Gly Ser Val Phe Leu Ser Ala Gin His Asp Arg 405 410 415 gga cat gtc gac caa ctg gtg teg ace ttt gat tec att ctt ggc cgc 1352 Gly His Val Asp Gin Leu Val Ser Thr Phe Asp Ser He Leu Gly Arg 420 425 430 ctg get gaa gaa aac etc ctg ggc taagccetta eacatetgtc tggaatatga 1406 Leu Ala Glu Glu Asn Leu Leu Gly 435 440 atcatgaaaa etagcctgaa a 1427 Annexe 3.2 [SEQ ID : No . 22] [D-p-hydroxyphenylglycine aminotransferase from Pseudomonas putida NCIMB 12565] Met Ser He Tyr Ser Asp Tyr Glu Arg Lys Thr Val Gly Ser Ala His 1 5 10 15 Trp Ala Asp Arg Ala Arg Ala Val Met Pro Asp Gly Val Thr Ala Asp 20 25 30 Thr Arg Val Phe Asp Pro His Gly Leu Tyr He Cys Asp Ala Gin Gly 35 40 45 Val His Lys Thr Asp Val Asp Gly Asn Val Tyr Leu Asp Phe Phe Gly 50 55 60 • Gly His Gly Ala Leu Val Leu Gly His Gly His Pro Arg He Asn Lys 65 70 75 80 Ala He Ser Ala Ala Leu Thr His Gly Val Gin Tyr Gly Ala Ser His 85 90 95 Pro Leu Glu Val Arg Trp Ala Glu Arg Leu Val Asn Ala Phe Pro Ser 100 105 110 Met His Lys Val Arg Phe Ala Gly Ser Gly Thr Glu Ala Thr Leu Leu 115 120 125 Ala Leu Arg Met Ala Arg Ala Phe Thr Gly Arg Ser Lys He Leu Arg 130 135 140 He Ala Thr His Tyr His Gly Trp His Asp Phe Ser Ala Ser Gly Tyr 145 150 155 160 Asn Ser His Phe Asp Gly Gin Pro Ala Pro Gly Val Leu Ala Glu He 165 170 175 Ala Gin Ser Thr Leu Leu Val Arg Pro Asp Asp Phe Glu Gly Leu Arg 180 185 190 Ala Leu Phe Ala Gin Tyr Gly Gly Glu He Ala Thr He He Ala Glu 195 200 205 Pro Val Gly Ser His Phe Gly He Thr Pro Val Ser Asp Asp Phe Leu 210 215 220 Leu Glu Gly Ala Ala Leu Ala Arg Lys His Gly Ala He Phe He Leu 225 230 235 240 Asp Glu Val He Thr Gly Phe Arg Val Gly Asn His Gly Met Gin Gly 245 250 255 Leu Leu Asp He Ala Pro Asp Leu Thr Cys Leu Ala Lys Ala Ser Ala 260 265 270 Gly Gly Leu Pro Gly Gly Val Val Gly Gly Arg Ala Asp Val Met Ala 275 280 285 Val Leu Asp Arg Gly Ser Asp Arg Lys Val Leu His Gin Gly Thr Phe 290 295 300 Thr Gly Asn Pro He Thr Ala Ala Ala Ala He Ala Ala He Asp Thr 305 310 315 320 He He Glu Asp Asp Val Cys Thr His He Asn Ala Leu Gly Gin Tyr 325 330 335 Ala Arg Asp Ser Met Asn Glu Leu Phe Ala Arg Lys His Leu Asp Trp 340 345 350 Leu Ala Tyr Gly Arg Phe Ser Gly Phe His Leu Met Pro Gly Leu Ser 355 360 365 Pro Leu Thr Thr Asp Thr Gly Val He Thr Arg Gly Glu Val Ala Arg 370 375 380 Pro Ala Val Lys Met He Ala Ala Met Arg Met Ala Leu He Leu Glu 385 390 395 400 Gly He Asp He Gly Gly Arg Gly Ser Val Phe Leu Ser Ala Gin His 405 410 415 Asp Arg Gly His Val Asp Gin Leu Val Ser Thr Phe Asp Ser He Leu 420 425 430 Gly Arg Leu Ala Glu Glu Asn Leu Leu Gly 435 440 Annexe 4 Sequence listings of oligonucleotides [SEQ ID: No.1] gtceaeggte tcecatgeag aatttcgaga t 31 [SEQ ID: No.2] acatcccaag cttcacgttc gaggtc 26 [SEQ ID: No.3] cgctcggtca tgacgtacgt ttccctg 27 [SEQ ID: No.4] acgaagaagc ttatcaaaca acccccag 28 [SEQ ID: No.5] atgccgccca gtgacatcgc gtacgc 26 [SEQ ID: No.6] ceetcggtac caggtcatcg gccggecact tec 33 [SEQ ID: No.7] atgcgggagc cgctcacgct cgac 24 [SEQ ID: No.8] ccaactggta ectggtcate cgtggctcet gtctcg 36 [SEQ ID: No.11] agaattcgcg gcacaggcag gcagcg 26 [SEQ ID: No.12] ttataagctt tcagcgctcg gtccggtggc 30 [SEQ ID: No.13] tataccatgg cggcacaggc aggc 24 [SEQ ID: No.14] ttataagctt gcgctcggtc cggtggc 27 [SEQ ID : No . 17 ] agaattcggc gtccgcaact ccgcag 26 [SEQ ID: No.18] aataagcttt cagggcgcac ctcgcc 26 [SEQ ID: No.19] actcgccaag ggctatggtg tec 23 [SEQ ID: No.20] gccaacagtt ccaacagcgg tgtg 24 [SEQ ID: No.23] gtgcaeggtc tegcatgtct atttatagcg attatgaaeg taaaac 46 [SEQ ID: No.24] gtgcaeggtc teetcgagtt agcccaggag gttttcttca gc 42 [SEQ ID: No.25] gggaatteag gaggaattaa ceatgccgcc gagcgae 37 [SEQ ID: No.26] gaattcccat attctagaag gtcatcggcc ggccact 37 [SEQ ID: No.27] tgggaattca ggaggaatta accatgcag 29 [SEQ ID: No.28] cggccaggtc tagatacgtc atcgccg 27 [SEQ ID: No.29] tgggtctaga ggaggaatta accatgcgcg agccg 35 [SEQ ID: No.30] gaattcccat agcatgcctg gtcatccgtg gctcc 35 [SEQ ID: No.31] tttcccaagc ttacaggagg aattaaccat g 31 [SEQ ID: No.32] gtaccagctg caaagcttga gttagcccag 30 [SEQ ID : No . 33] gggtctagag gaggaattaa ccatgagcca gaatctcttt 40 [SEQ ID: No.34] ctgeagaace ageatggtgg tcagtactte acteatgeg 39 [SEQ ID: No.35] gcgtggaagc ttaagaggtt tattatggtt gctgaa 36 [SEQ ID: No.36] gtgcaeggtc tcgagctgaa ttcttaetgg egattgteat 40

Claims: CLAIMS 1. A fermentative process in which a recombinant microorganism produces D-phenylglycine (D-PG) or D-p-hydroxyphenylglycine (D-HPG), wherein a) for the production of D-PG, respectively for the production of D-HPG, phenylpyruvate, respectively p-hydroxyphenylpyruvate is withdrawn from the aromatic amino acid pathway b) and is converted to mandelic acid or p-hydroxymandelic acid, respectively, c) thereafter being converted into phenylglyoxylate or p-hydroxyphenylglyoxylate, respectively, d) and the phenylglyoxylate or p-hydroxyphenylglyoxylate thereafter being converted into D-phenylglycine or D-p-hydroxyphenylglycine by the action of a stereo-inverting D-aminotransferase, respectively. 2. A process according to claim 1 , wherein the microorganism applied provides phenylpyruvate or p-hydroxyphenylpyruvate at increased availability. 3. A process according to claim 2, wherein phenylpyruvate or p-hydroxyphenylpyruvate is provided at increased availability by feeding phenylalanine (for phenylpyruvate) or tyrosine (for p-hydroxyphenylpyruvate), respectively. 4. A process according to any of claims 1-3, wherein the conversion of phenylpyruvate to mandelic acid or the conversion of p-hydroxyphenylpyruvate to p-hydroxymandelic acid , occurs Via a one-step enzymatic reaction catalyzed by a p-hydroxymandelate synthase. 5. A process according to any of claims 1-3, wherein the conversion of phenylpyruvate to mandelic acid or the conversion of p-hydroxyphenylpyruvate to p-hydroxymandelic acid occurs via a multi-step reaction, comprising the steps of converting PP or HPP to phenylacetaldehyde or p-hydroxyphenylacetaldehyde, then to phenylacetate or p-hydroxyphenylacetate, and finally to MA or HMA, respectively. 6. A process according to any of claims 1-5, wherein the conversion of p-hydroxymandelate, respectively mandelate, to p-hydroxyphenylglyoxylate, respectively to phenylglyoxylate is catalyzed in the presence of an enzyme, selected from a group of enzymes, consisting of mandelate dehydrogenase, p-hydroxymandelate dehydrogenase, oxygen dependent mandelate oxidases, and oxygen dependent p-hydroxymandelate oxidases. 7. A recombinant cell which is capable of secreting detectible amounts of D-HPG or D-PG and which contains a) genes coding for enzymes which catalyze the conversion of p-hydroxyphenylpyruvate to p-hydroxymandelic acid or phenylpyruvate to mandelic acid b) genes coding for enzymes which catalyze the conversion of p-hydroxymandelic acid to p-hydroxyphenylglyoxylate or of mandelic acid to phenylglyoxylate c) and genes coding for a stereo-inverting D-aminotransferase which catalyzes the conversion of p-hydroxyphenylglyoxylate to D-HPG or phenylglyoxylate to D-PG. 8. A recombinant plasmid containing at least one gene having a sequence corresponding with any of [SEQ ID: No.9] and/or [SEQ ID: No.15] and/or [SEQ ID: No.21], as disclosed in this application, or homologues of any of these sequences having at least 80%, preferably at least 90%, most preferably at least 95% homology with any of such sequences.

Inventors: ASSEMA VAN FRISO BERNARD JAN, GUNSIOR MICHELE, MUELLER ULRIKE, SONKE THEODORUS, TOWNSEND CRAIG A, ASSEMA VAN, FRISO, BERNARD, JAN, GUNSIOR, MICHELE, MUELLER, ULRIKE, SONKE, THEODORUS, TOWNSEND, CRAIG, A.
Applicants: ASSEMA VAN FRISO BERNARD JAN, DSM BIOTECH GMBH, DSM NV, GUNSIOR MICHELE, MUELLER ULRIKE, SONKE THEODORUS, TOWNSEND CRAIG A, UNIV JOHNS HOPKINS, ASSEMA VAN, FRISO, BERNARD, JAN, DSM N.V., GUNSIOR, MICHELE, JOHNS HOPKINS UNIVERSITY, MUELLER, ULRIKE, SONKE, THEODORUS, TOWNSEND, CRAIG, A.
Application year: 2001
Main classification: C12N15
IPC codes: C12N1, C12N9, C12N15, C12P21